MARKET WIREBenzinga • 2d ago
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $9Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $10 to $9.
Why NAGE Stock slipped -1.57% Today — RQD Quant Desk Flash
$2.50 -1.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.49
Niagen Bioscience Inc. (NAGE) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $197.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NAGE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.50 (-1.57% 1D, market cap $197.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NAGE compare to GLAS and MDWD in the Health Care sector?
▼
Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable D+ (57/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NAGE?
▼
Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.49 (-0.47%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 10.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NAGE)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY NAGE SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (32% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)
Altman Z-Score 4.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$2.63-4.9% Next Q
65
Q2 (-2Q)Grade C+$2.50-2.4% Next Q
62
Q3 (-1Q)Grade C$2.44+2.5% Next Q
60
CurrentGrade D+$2.50-0.2% Hist 90D α
57
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NAGE Bull Thesis Could Fail
Even with a 57/100 (D+) score, NAGE faces multiple-compression risk if 11.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 61.8% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.84) or 200D SMA ($3.90) invalidates the momentum regime and cuts Target Base ($2.49) toward Bear Floor ($1.94).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NAGE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NAGE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NAGE Stock slipped -1.57% Today — RQD Quant Desk Flash
Niagen Bioscience Inc. (NAGE) slipped -1.57% to $2.50, trading at 3% of its 52-week range ($2.32 – $7.95). Stretched risk/reward at 11x P/E (17% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($2.32 – $7.95) with RSI-14 at 43.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $2.50 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: NAGE Exhibits 2.64x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live NAGE Headlines & Catalysts
CATALYSTYahoo • 4d ago
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineNiagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREYahoo • 10d ago
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth ExpansionLOS ANGELES, October 22, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of the clin
MARKET WIREYahoo • 12d ago
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® ProductLOS ANGELES, October 20, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niage
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NAGE)
- ✓Walkthrough of NAGE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NAGE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.29%⚡ TESTING RESISTANCE
2026-11-02O $2.54H $2.54L $2.50C $2.50VOL 348.4K
RES: $2.69SUP: $2.13SMA50: $2.84SMA200: $3.90
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NAGE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
1.5%/yr Implied 5Y Growth
vs. +29.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NAGE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NAGE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NAGE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NAGE)
Health Care Rank #212 of 1016
⚔️ GLAS vs NAGE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NAGE vs. GLAS, MDWD, ACB, USNA)
Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Niagen Bioscience Inc. (NAGE) ranks #212 by composite RQD confidence (57/100, grade D+) and #580 by equity capitalization ($197.8M). Within this direct 5-issuer industry benchmark cohort, NAGE leads on earnings valuation at 11.4x trailing P/E, while NAGE leads on capital efficiency and profitability with 16.8% ROIC and 64.3% gross margin. NAGE currently leads its immediate peer cohort in composite quantitative strength at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NAGE
ACTIVE
Niagen Bioscience Inc. | D+ | 57/100 | 11.4x | 64.3% | 16.8% | -1.57% | $197.8M | Benchmark Subject |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | E | 18/100 | — | 42.3% | -9.2% | +1.33% | $200.6M | /glas-vs-nage → |
| MDWD MediWound Ltd. | D | 51/100 | — | — | — | +2.21% | $178.9M | /mdwd-vs-nage → |
| ACB Aurora Cannabis Inc. | D+ | 54/100 | — | — | — | 0.00% | $252.8M | /acb-vs-nage → |
| USNA USANA Health Sciences Inc. | D | 50/100 | 24.6x | 78.3% | 7.9% | -1.91% | $265.0M | /usna-vs-nage → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001386570In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niagen Bioscience Inc. (NAGE) reported GAAP revenue of $129.4M (+29.9% vs. FY2024 revenue of $99.6M , and +54.9% cumulative change since FY2023) , GAAP net income of $17.4M, operating cash flow of $13.5M, and free cash flow of $13.5M (+11.5% YoY). On the balance sheet, NAGE closed FY2025 with $106.4M in total assets against $0 in total debt (Altman Z-Score: 4.40, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $129.4M | $17.4M | $13.5M | $13.5M | $106.4M | — |
| FY2024 (FY) | 2024-12-31 | $99.6M | $8.6M | $12.1M | $12.1M | $68.3M | — |
| FY2023 (FY) | 2023-12-31 | $83.6M | -$4.9M | $7.1M | $7.1M | — | — |
3. NAGE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NAGE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Niagen Bioscience Inc. (NASDAQ: NAGE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $2.50 (-1.57% 1D, market cap $197.8M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 18/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does NAGE compare to GLAS and MDWD in the Health Care sector?
Within the Health Care sector (Medicinal Chemicals and Botanical Products), NAGE carries a Roarable D+ (57/100 RQD), trailing P/E of 11.4x, gross margin of 64.3%, and ROIC of 16.8%. By comparison, GLAS (Glass House Brands Inc. Subordinate Voting Shares) holds a E grade (18/100 RQD, P/E N/A, ROIC -9.2%, cap $200.6M) and MDWD (MediWound Ltd.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $178.9M). Among the 5-stock peer group, NAGE leads on earnings multiple (11.4x) while NAGE leads on capital efficiency (16.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NAGE?
Per NAGE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001386570), Niagen Bioscience Inc. generated $129.4M in revenue (+29.9% YoY), $17.4M in net income, and $13.5M in free cash flow against $106.4M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NAGE trading relative to its 50-day, 200-day, and 52-week technical levels?
NAGE last traded at $2.50 (-1.57% on volume of 348,392 shares), positioning the stock -11.97% below its 50-day simple moving average ($2.84) and -35.90% below its 200-day simple moving average ($3.90). Across its 52-week range of $2.32 to $7.95, NAGE sits at the 3.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($2.32 to $2.68).
NAGE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NAGE stock moving today?
Why NAGE Stock slipped -1.57% Today — RQD Quant Desk Flash. Stretched risk/reward at 11x P/E (17% return on capital) under elevated 10-year interest-rate pressure.